| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02298153 Details | 2017-12-11 Interventional | 1 | 29 | Atezolizumab Carcinoma Carcinoma, Non-… Carcinoma, Tran… NSCLC (Non-smal… UC (Urothelial … | Study halted prematurely and will not resume; participants are no longer being examined or
receiving intervention. - | |||
| NCT01934192 Details | 2017-12-11 Interventional | 2 | 91 | Metoclopramide Critical Illnes… Gastroparesis | - - | |||
| NCT01890694 Details | 2017-12-11 Interventional | 4 | 2 | Tolvaptan Hyponatremia | - Due to the small sample size, data was not able to be analyzed. | |||
| NCT03266159 Details | 2017-12-08 Interventional | 2 | 0 | Trametinib Solid Tumours | Study withdrawn before active to fully evaluate impact of changing practice in target
population. - | |||
| NCT00226941 Details | 2017-12-08 Interventional | 1/2 | 23 | Capecitabine Cetuximab Diphenhydramine Oxaliplatin Promethazine Rectal Neoplasm… Colo-rectal Can… Rectal Cancer | The response rate observed in the phase 1 portion of the study did not merit further evaluation
in phase 2 portion of the study. This trial was halted after the phase 1 portion of enrollment, and before the phase 2 portion accrued. Data reported for phase 2 objectives/outcomes do not include any phase 2 participants, and are only provided for completeness. | |||
| NCT01345669 2011-000392-14 Details | 2017-12-07 Interventional | 3 | 617 | Afatinib Head and Neck N… | - The trial was stopped prematurely due to futility. | |||
| NCT00460759 Details | 2017-12-07 Interventional | 1 | 15 | Moxifloxacin Rifapentine Mycobacterium I… Tuberculosis Mycobacterium T… | - - | |||
| NCT03245671 Details | 2017-12-06 Interventional | 4 | 0 | BB 1101 Dexamethasone Dexamethasone 2… Dexamethasone a… Triamcinolone A… Constriction, P… Spinal Stenosis Lumbar Spinal S… | Unable to address regulatory concerns. - | |||
| NCT02049801 Details | 2017-12-06 Interventional | 1 | 1 | Cytarabine Idarubicin Leukemia Leukemia, Eryth… Leukemia, Monoc… Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Adult Acute Min… Adult Acute Mon… Adult Acute Mon… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Erythrole… Adult Pure Eryt… Recurrent Adult… | logistics - | |||
| NCT01908803 Details | 2017-12-06 Interventional | 2 | 84 | Ciprofloxacin Dexamethasone Otitis Otitis Media Acute Otitis Me… | Management decision - | |||
| NCT01740401 Details | 2017-12-06 Interventional | 2 | 10 | Cyclophosphamid… Ipilimumab Melanoma | Primary Endpoint not met - | |||
| NCT02452528 Details | 2017-12-05 Interventional | 2 | 4 | Diphenhydramine Entecavir Promethazine Tenofovir Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… Hepatitis, Chro… Chronic Hepatit… | Company decision to discontinue trial - | |||
| NCT01343368 Details | 2017-12-05 Interventional | 2 | 19 | Leuprolide Hodgkin Disease Multiple Myelom… Myeloproliferat… Acute Myeloid L… Non-Hodgkin Lym… | - - | |||
| NCT01342770 Details | 2017-12-05 Interventional | 2 | 6 | Pioglitazone Carcinoma Carcinoma, Non-… Lung Neoplasms Stage IA Non-Sm… Stage IB Non-Sm… Stage IIA Non-S… Stage IIB Non-S… Stage IIIA Non-… | - - | |||
| NCT00655824 Details | 2017-12-05 Interventional | 2 | 124 | Ofatumumab Arthritis Arthritis, Rheu… | The clinical development of intravenously administered ofatumumab in RA will no longer be
pursued, so this study was prematurely terminated by the Sponsor. Development of the IV route of ofatumumab (OFA) administration in RA will no longer be pursued. This study was prematurely terminated; OFA treatment was discontinued. Participants could complete only <=7 treatment courses and a follow-up evaluation. | |||
| NCT00176839 Details | 2017-12-05 Interventional | 2/3 | 11 | Antilymphocyte … Busulfan Cyclophosphamid… Lenograstim Melphalan Hematologic Neo… Leukemia, Lymph… Neoplasms Precursor Cell … AML Leukemia, Lymph… MDS | Replaced by a different study - | |||
| NCT02350426 Details | 2017-12-04 Interventional | 1 | 10 | Fluorodeoxygluc… Arthritis Arthritis, Rheu… Inflammation | A decision to stop the study was made by the site and GSK project team based on pre-defined
stopping criteria in the protocol - | |||
| NCT02138825 2010-024332-42 Details | 2017-12-04 Interventional | 2 | 147 | Riociguat Hamman-Rich Syn… Hypertension Hypertension, P… Idiopathic Inte… Lung Diseases, … Pneumonia Pulmonary Fibro… Idiopathic Inte… | Study terminated per recommendation of iDMC. On iDMC request, protocol amended to include
4-month safety follow-up for patients after withdrawal of riociguat. The study was prematurely terminated following a recommendation from the independent Data Monitoring Committee, as patients receiving Riociguat showed an increased risk of mortality and serious adverse events as compared to patients receiving Placebo | |||
| NCT02118311 Details | 2017-12-02 Interventional | 2 | 0 | Cyclophosphamid… Fludarabine Hematologic Neo… Neoplasms Hematologic Mal… | Changing study design. Will replace with a different protocol. - | |||
| NCT01639456 Details | 2017-12-02 Interventional | 2 | 0 | Aldesleukin Cyclophosphamid… Fludarabine Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myelogeno… | study was abandoned and a new study was written to replace this one - |